Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00326235 · ClinicalTrials.gov registry record · Phase 4
Effects of Buspirone in Opiate Withdrawal
A Phase 4 study of Heroin Dependence, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Study location
NCT00326235 is a Phase 4 study of Heroin Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The trial reports 1 study location across 1 state.
The verdict
NCT00326235, a Phase 4 study of Heroin Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1
- Study location
Study Summary
Dependence on heroin is a major public health problem because of its association with criminality, law enforcement costs and healthcare costs. Managed withdrawal is a required first step for a long term drug-free treatment of heroin addicts. Methadone and clonidine have been the mainstay of treatment for the relief of heroin withdrawal symptoms but both have limitations. The purpose of this study was to evaluate the efficacy of buspirone in the alleviation of the withdrawal symptoms experienced by heroin addicts when they stop using heroin. Buspirone is a non opiate drug with no abuse potential, no sedating effects and no withdrawal symptoms.
Conditions Studied
Interventions
- DRUG Buspirone
Study Locations (1)
New York
- VA New York Harbor Healthcare System - Brooklyn Campus - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Est. Completion | 2004-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00326235
The ClinicalTrials.gov registry entry for NCT00326235 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heroin Dependence appearing as the primary indexed condition, and to 1 intervention - of which Buspirone is the first listed.
NCT00326235 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00326235 about?
NCT00326235 is a clinical study titled "Effects of Buspirone in Opiate Withdrawal". Dependence on heroin is a major public health problem because of its association with criminality, law enforcement costs and healthcare costs. Managed withdrawal is a required first step for a long term drug-free treatment of heroin addicts. Methadone and clonidine have been the mainstay of treatmen...
What is the current status of trial NCT00326235?
This trial is currently completed. It is a Phase 4 study. The study started on 2002-01. Estimated completion is 2004-07.
What conditions does trial NCT00326235 study?
This clinical trial studies the following conditions: Heroin Dependence.
What interventions are being tested in trial NCT00326235?
The interventions under investigation include: Buspirone (DRUG).
Who is sponsoring clinical trial NCT00326235?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00326235 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heroin Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
COMPLETED · Phase 3
-
Directly Administered HIV Therapy in Methadone Clinics
COMPLETED · Phase 2
-
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
COMPLETED · Phase 2
-
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
COMPLETED · Phase 3
-
Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1
COMPLETED · Phase 2
-
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.